Merus (NASDAQ:MRUS) Stock

Merus

Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.

Merus NV

WIIM

MRUS

Merus shares are trading lower following its $300 million public offering announcement.

U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 0.1% on Wednesday.
Shares of CrowdStrike Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) fell sharply in today's pre-market trading after the company <a href="https://www.benzinga.com/quote/crwd/earnings">reported first-quarter results.</a>
CrowdStrike posted better-than-expected earnings for the first quarter and also raised its full-year guidance. However, the company said it expects second-quarter revenue to be between $1.145 billion and $1.152 billion versus estimates of $1.23 billion. The company anticipates second-quarter adjusted earnings of 82 cents to 84 cents per share versus estimates of 92 cents per share.
CrowdStrike shares dipped 7% to $454.70 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>Asana, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASAN#NYSE">ASAN</a>) shares dipped 8.4% to $17.40 in today's pre-market trading after the company reported first-quarter results.</li>
<li>Outset Medical Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OM#NASDAQ">OM</a>) declined 6.8% to $18.09 in pre-market trading. Outset Medical named Renee Gaeta as CFO, effective immediately.</li>
<li>Merus NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) declined 5.5% to $59.01 in pre-market trading. Merus priced $300 million public offering of 5,263,158 common shares at $57 per share.</li>
<li>Quidelortho Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>) shares declined 4.3% to $29.00 in pre-market trading.</li>
<li>ATAI Life Sciences NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) fell 3.4% to $2.27 in pre-market trading after declining more than 5% on Tuesday.</li>
<li>Doximity Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) fell 2.7% to $52.06 in pre-market trading after gaining around 4% on Tuesday.</li>
</ul>
Now Read This:<a href="Cramer: Should've Told Investors To 'Pull The Trigger' On Trade Desk, Can't Believe 'How Low' Gentex Has Fallen"> </a>
<ul class="wp-block-list">
<li><a href="Cramer: Should've Told Investors To 'Pull The Trigger' On Trade Desk, Can't Believe 'How Low' Gentex Has Fallen">Cramer: Should&#8217;ve Told Investors To &#8216;Pull The Trigger&#8217; On Trade Desk, Can&#8217;t Believe &#8216;How Low&#8217; Gentex Has Fallen</a></li>
</ul>
Photo via Shutterstock

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ASAN

ATAI

CRWD

DOCS

QDEL

CrowdStrike, Asana And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Merus Prices $300M Public Offering Of 5,263,158 Common Shares At $57/Share

Merus shares are trading lower after the company announced a proposed public offering.

Offerings

Merus Announces Proposed Public Offering Of Common Shares; Size Not Disclosed

These eleven mid-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol class="wp-block-list">
<li>LZ Technology Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LZMH#NASDAQ">LZMH</a>) shares surged 78.57% last week.</li>
<li>Centrus Energy Corp. (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LEU#AMEX">LEU</a>) shares rose 36.22% as President Donald Trump signed a suite of executive orders aimed at <a href="https://www.benzinga.com//node/45654523" target="_blank" rel="noreferrer noopener">reviving the U.S. nuclear industry.</a></li>
<li>e.l.f Beauty, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) stock escalated 35.89% after it reported better-than-expected quarterly results and announced it would acquire Hailey Bieber&#8217;s <a href="https://www.benzinga.com//node/45677382" target="_blank" rel="noreferrer noopener">Brand Rhode for $1 billion</a>. Analysts raised the <a href="https://www.benzinga.com/quote/elf/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast on the stock</a>.</li>
<li>Merus N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) stock increased 34.78%.</li>
<li>Oklo Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) stock was up 32.73% due to executive orders signed by Trump to <a href="https://www.benzinga.com//node/45654523" target="_blank" rel="noreferrer noopener">revive the U.S. nuclear industry.</a></li>
<li>NuScale Power Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) shares upped 26.32%.</li>
<li>Informatica Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INFA#NYSE">INFA</a>) shares jumped 25.05% after the company announced that Salesforce, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) would acquire them for approximately $8 billion, and analysts <a href="https://www.benzinga.com//node/45647236" target="_blank" rel="noreferrer noopener">revised the price forecast</a>.</li>
<li>BRP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOOO#NASDAQ">DOOO</a>) stock escalated 22.29% after the company reported better-than-expected first-quarter results. Additionally, the company announced that its president, CEO, and chair of the board will retire <a href="https://www.benzinga.com//node/45664327" target="_blank" rel="noreferrer noopener">by the end of the fiscal year</a>. Analysts raised the <a href="https://www.benzinga.com/quote/dooo/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast/ rating on the stock</a>.</li>
<li>Box (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOX#NYSE">BOX</a>) stock grew 20.99% after the company reported better-than-expected first-quarter financial results, and analysts revised the <a href="https://www.benzinga.com//node/45646700" target="_blank" rel="noreferrer noopener">price forecast on the stock</a>.</li>
<li>Joby Aviation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>) stock upped 17.77% after the company announced closing a <a href="https://www.benzinga.com//node/45643642" target="_blank" rel="noreferrer noopener">$250 million investment</a> from Toyota Motor Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TM#NYSE">TM</a>).</li>
<li>C3.ai, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AI#NYSE">AI</a>) shares rose 16.98% after the company reported better-than-expected fourth-quarter financial results and announced a renewal and expansion of its joint venture with Baker Hughes for accelerated AI-driven transformations <a href="https://www.benzinga.com//node/45657936" target="_blank" rel="noreferrer noopener">in the energy and industrial sectors</a>. Analysts revised the <a href="https://www.benzinga.com/quote/ai/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast on the stock</a>.</li>
</ol>
Photo by LisaChi via Shutterstock

Mid Cap

DOOO

INFA

JOBY

LZMH

OKLO

e.l.f Beauty, Box And Joby Aviation Are Among Top 11 Mid-Cap Gainers Last Week (May 26-May 30): Are Others In Your Portfolio?

These mid-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol class="wp-block-list">
<li>D-Wave Quantum Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) shares jumped 53.47% after the company announced it launched its Advantage2 quantum system to address problems in optimization, <a href="https://www.benzinga.com//node/45518005" target="_blank" rel="noreferrer noopener">AI, and materials simulation</a>.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock gained 42.49% last week.</li>
<li>Advance Auto Parts Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>) stock increased 38.94%  after the company <a href="https://www.benzinga.com//node/45567507" target="_blank" rel="noreferrer noopener">reported first-quarter results</a>. Several analysts raised the <a href="https://www.benzinga.com/quote/aap/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast on the stock</a>.</li>
<li>Merus N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) stock rose 32.68% after the company disclosed interim clinical data as of a February 27, 2025, data cutoff from the ongoing phase 2 trial of the bispecific antibody petosemtamab in <a href="https://www.benzinga.com//node/45576972" target="_blank" rel="noreferrer noopener">combination with pembrolizumab</a>.</li>
<li>Oklo Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) shares upped 29.56%, probably due to reports indicating that Trump will sign executive orders to ease regulatory <a href="https://www.benzinga.com//node/45590362" target="_blank" rel="noreferrer noopener">requirements for new reactors</a>.</li>
<li>Sibanye-Stillwater Limited ADS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBSW#NYSE">SBSW</a>) shares were up 29.26%.</li>
<li>BGM Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGM#NASDAQ">BGM</a>) stock gained 27.20% last week.</li>
</ol>
Photo via Shutterstock

Equities

QBTS

SBSW

D-Wave Quantum And Advance Auto Parts Are Among Top 7 Mid-Cap Gainers Last Week (May 19-May 23): Are The Others In Your Portfolio?

Merus N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) shares are trading higher Friday after the company reported promising interim results from its ongoing phase 2 trial evaluating petosemtamab in combination with pembrolizumab for <a href="https://www.benzinga.com/pressreleases/25/05/g45576972/merus-petosemtamab-with-pembrolizumab-interim-data-demonstrates-robust-efficacy-and-durability-in-">head and neck cancer.</a>
What To Know: The data, which will be formally presented at the 2025 ASCO Annual Meeting, showed a 63% overall response rate and a 79% 12-month overall survival rate among 43 evaluable patients with PD-L1+ recurrent/metastatic head and neck squamous cell carcinoma.
The trial also reported a median progression-free survival of nine months, with six patients achieving complete responses and 21 showing partial responses. Importantly, no significant overlapping toxicities were observed in the treatment combination, which was generally well tolerated. Merus noted that 14 responders remained on therapy at the time of the Feb. 27 2025 data cutoff.
Analysts Weigh In: Needham raised its price target on Merus from $75 to $88, stating the updated data meaningfully de-risk the ongoing phase 3 trials. BMO Capital also raised its target from $96 to $110.
Topline data from one or both of the ongoing phase 3 studies are expected in 2026. 
MRUS Price Action: Merus shares were up 34.9% at $56.11 at the time of writing, according to<a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2"> Benzinga Pro.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45592743/stocks-bitcoin-fall-on-trumps-tariff-threats-gold-rallies-whats-driving-markets-friday">Stocks, Bitcoin Fall On Trump&#8217;s Tariff Threats, Gold Rallies: What&#8217;s Driving Markets Friday? </a></li>
</ul>
Image Via Shutterstock.

Merus Stock Surges Over 35% On Strong Phase 2 Cancer Trial Results: What's Going On?

Merus shares are trading higher after the company reported interim clinical data form the ongoing phase 2 trial of petosemtamab in combination with pembrolizumab. Multiple analysts raised their price targets on the stock.

BMO Capital analyst Evan David Seigerman maintains Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Outperform and raises the price target from $96 to $110.

Price Target

Analyst Ratings

BMO Capital Maintains Outperform on Merus, Raises Price Target to $110

U.S. stocks were lower, with the Dow Jones index falling around 300 points on Friday.
Shares of Frontline plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRO#NYSE">FRO</a>) rose during Friday's session <a href="https://www.benzinga.com/quote/FRO/earnings">following first-quarter results</a>.
The company reported revenue of $427.9 million, surpassing the $264.2 million consensus. Adjusted EPS declined to 18 cents from 62 cents a year ago, missing the consensus of 23 cents.
Frontline shares gained 3.7% to $17.81 on Friday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul class="wp-block-list">
<li>Merus N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) shares jumped 30% to $54.04 as the company disclosed interim clinical data as of a February 27, 2025 data cutoff from the ongoing phase 2 trial of the bispecific antibody petosemtamab in combination with pembrolizumab.</li>
<li>NANO Nuclear Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNE#NASDAQ">NNE</a>) rose 24.7% to $34.40.</li>
<li>Centrus Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEU#NYSE">LEU</a>) gained 23.4% to $114.98.</li>
<li>Oklo Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) rose 23.1% to $49.03 after Wedbush raised its price target on the stock from $45 to $55 and maintained an Outperform rating.</li>
<li>Centrus Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEU#NYSE">LEU</a>) gained 23.1% to $114.80.</li>
<li>Uranium Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UEC#NYSE">UEC</a>) gained 19.2% to $6.15.</li>
<li>NuScale Power Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) shares gained 16% to $29.36.</li>
<li>NexGen Energy Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NXE#NYSE">NXE</a>) rose 11.6% to $6.07.</li>
<li>Intuit Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) gained 8.8% to $724.54 after the company reported better-than-expected third-quarter financial results and raised guidance.</li>
<li>Cameco Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCJ#NYSE">CCJ</a>) rose 8.2% to $57.13.</li>
<li>BWX Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWXT#NYSE">BWXT</a>) gained 6.5% to $114.70.</li>
<li>Fluor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLR#NYSE">FLR</a>) rose 5.4% to $39.61.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45585296/jim-cramer-says-medical-properties-trust-has-too-much-risk-likes-this-industrial-stock">Jim Cramer Says Medical Properties Trust Has &#8216;Too Much Risk,&#8217; Likes This Industrial Stock</a> </li>
</ul>
Photo via Shutterstock

Intraday Update

BWXT

INTU

Nuveen Arizona Dividend Advantage Municipal Funds 3

Frontline, Merus, Intuit And Other Big Stocks Moving Higher On Friday

Merus shares are trading higher after Needham raised its price target on the stock from $75 to $88.

Needham analyst Ami Fadia maintains Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Buy and raises the price target from $75 to $88.

Needham Maintains Buy on Merus, Raises Price Target to $88

-&nbsp; 63% response rate observed among 43 evaluable patients
-&nbsp; 79% overall survival rate at 12-months; 9 months median progression-free survival
-&nbsp; Conference Call on Thursday, May 22 at 5:30 p.m. ET &nbsp;
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=9FhYyVwI9DsnInrbxOt--inJgjOKfmMbph8kfn71rg_QOcr1YnuZK2hzrUydrWlBOD1YgWDc-HEZ2Du9ltkH1g==">Merus N.V.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics&#xAE;, Triclonics&#xAE; and ADClonics&#xAE;), today announced interim clinical data as of a February 27, 2025 data cutoff from the ongoing phase 2 trial of the bispecific antibody petosemtamab in combination with pembrolizumab. These data will be presented by Dr. Carla M. L. van Herpen M.D. Ph.D., Radboud University Medical Center, Nijmegen, Netherlands at the 2025 American Society of Clinical Oncology&#xAE; (ASCO&#xAE;) Annual Meeting on Monday, June 2 at 9 a.m. - 12:00 p.m. CT.

Biotech

General

Merus Reports Interim Phase 2 Data Showing 63% Response Rate And 79% 12-Month Overall Survival For Petosemtamab Plus Pembrolizumab In Ongoing Trial, To Be Presented At ASCO 2025 With Conference Call Scheduled For May 22

Needham analyst Ami Fadia reiterates Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Buy and maintains $75 price target.

Reiteration

Needham Reiterates Buy on Merus, Maintains $75 Price Target

<a href="https://www.globenewswire.com/Tracker?data=1Cv5vc6xPugdycgEI5g5MdjtOphqPViQBh2de9Wew2xQaCN7hVFga3quhCMOlC-V5wWvMzxJvQZavTaoOXF6bg==">Merus N.V.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) ("Merus", "the Company", "we", or "our"), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics&#xAE;, Triclonics&#xAE; and ADClonics&#xAE;), today announced publication on the mechanism of action of petosemtamab, a bispecific antibody targeting Epidermal Growth Factor Receptor (EGFR) and Leucine-Rich G (LGR5), in the scientific journal "Cancers", a MDPI publication, available <a href="https://www.globenewswire.com/Tracker?data=qDy227Jlbf1q1FH5Gxy-pD1yN8G32hMajPBa7ZAAO61n2po-XuClGyspYfkeqMv_Yt_DqAC3_Jcym2YqyszV_3-VsruA190TW6MqqQ6agkc=">here</a>.

Merus Announces Publication On Mechanism Of Action Of Petosemtamab, Bispecific Antibody Targeting EGFR And LGR5, In Scientific Journal "Cancers"

Wells Fargo analyst Eva Fortea Verdejo maintains Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Overweight and lowers the price target from $91 to $89.

Wells Fargo Maintains Overweight on Merus, Lowers Price Target to $89

Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) reported quarterly losses of $(1.40) per share which missed the analyst consensus estimate of $(1.10) by 27.27 percent. This is a 137.29 percent decrease over losses of $(0.59) per share from the same period last year. The company reported quarterly sales of $26.49 million which beat the analyst consensus estimate of $7.82 million by 238.85 percent. This is a 235.76 percent increase over sales of $7.89 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Merus Q1 EPS $(1.40) Misses $(1.10) Estimate, Sales $26.49M Beat $7.82M Estimate

- Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC interim clinical data selected for poster presentation &nbsp;
- Conference call on&nbsp;Thursday, May 22&nbsp;at&nbsp;5:30 p.m. ET&nbsp;to discuss full ASCO&#xAE;&nbsp;data set
UTRECHT, The Netherlands&nbsp;and&nbsp;CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=yI2ecVsdRdXGdF2kI9WTwgqSchuYceNZul-sZuLiDMAEyEDBbIn5uDoCY8xIDJxN6qJWid8zPIakPcw51WnyrA==">Merus</a> N.V.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics&#xAE;, Triclonics&#xAE;&nbsp;and ADClonics&#xAE;), today announced the acceptance of an abstract for presentation at the 2025&nbsp;American Society of Clinical Oncology&#xAE;&nbsp;(ASCO&#xAE;) Annual Meeting, being held in&nbsp;Chicago, Illinois&nbsp;on&nbsp;May 30- June 3, 2025.
An updated analysis of the interim clinical data from the phase 2 trial of petosemtamab with pembrolizumab as 1L treatment of PD-L1+ recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC) will be presented in a poster at 2025 ASCO&#xAE;. The presentation will include data on the entire 45 patient dataset and follows the early clinical efficacy and encouraging safety data previously presented at 2024 ASCO&#xAE;.

Merus Says Petosemtamab In Combination With Pembrolizumab In 1L PD-L1+ R/M HNSCC Interim Clinical Data Selected For Poster Presentation At 2025 ASCO Annual Meeting

Needham analyst Ami Fadia reiterates Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Buy and maintains $83 price target.

Needham Reiterates Buy on Merus, Maintains $83 Price Target

Press Releases

Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update

Health Care

Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting

Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update

Merus to Present at BofA Securities 2025 Health Care Conference

Merus Announces the Journal Publication of Petosemtamab Mechanism of Action

Merus' Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC

Comments

Merus

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL